Bellicum Pharma: Gains on $15 mln sale plan for manufacturing plant

Bellicum Pharmaceuticals

21/01/2020 14:10

** Cancer drug developer's shares  BLCM.O  rise 13.1% to
$13.10 premarket 
    ** Says it will sell its Houston facility, including
manufacturing, office and lab space, to MD Anderson Cancer
Center for $15 mln  urn:newsml:reuters.com:*:nGNX5l3mKg
    ** Under the deal, MD Anderson will use the plant for its
own internal programs and also to manufacture BLCM's cell
therapies 
    ** "The ... agreement assures Bellicum's access to cell
therapy product supply while reducing our operating expenses" 
CEO Rick Fair
    ** Stock is down 32.3% in the past 12 months 

 (Reporting by Manas Mishra in Bengaluru)
 ((Manas.Mishra@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 806749 8325))